Evidence map›Paper›PMID 29996687›Full record

ArticleDrug delivery2018

Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.

David Warther, Ying Xiao, Fangting Li, Yuqin Wang, Kristyn Huffman, William R Freeman, Michael Sailor, Lingyun Cheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

David Warthera Department of Chemistry and Biochemistry , University of California , San Diego , CA , USA.
Ying Xiaob Department of Ophthalmology , Jacobs Retina Center at Shiley Eye Institute, University of California , San Diego , CA , USA.
Fangting Lib Department of Ophthalmology , Jacobs Retina Center at Shiley Eye Institute, University of California , San Diego , CA , USA.
Yuqin Wangb Department of Ophthalmology , Jacobs Retina Center at Shiley Eye Institute, University of California , San Diego , CA , USA.
Kristyn Huffmanb Department of Ophthalmology , Jacobs Retina Center at Shiley Eye Institute, University of California , San Diego , CA , USA.ORCID http://orcid.org/0000-0002-3271-2518
William R Freemanb Department of Ophthalmology , Jacobs Retina Center at Shiley Eye Institute, University of California , San Diego , CA , USA.
Michael Sailora Department of Chemistry and Biochemistry , University of California , San Diego , CA , USA.
Lingyun Chengb Department of Ophthalmology , Jacobs Retina Center at Shiley Eye Institute, University of California , San Diego , CA , USA.
University of California San Diego · USShandong University · CN

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Porous Silicon Particles for Sustained Intravitreal Drug DeliveryR01EY020617 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHENG, LINGYUN · 2011 to 2015
$2.6M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY020617
6 · The paper itself

Abstract

The number of blind and low vision persons in the US is projected to increase to 5.68 million by 2020. The eye diseases causing loss of vision are life-long, chronic, and often need protracted presence of therapeutics at the disease site to keep the disease in remission. In addition, multiple pathologies participate in the disease process and a single therapy seems insufficient to bring the disease under control and prevent vision loss. This study demonstrates the use of porous silicon (pSi) particles sequentially loaded with daunorubicin (DNR) and dexamethasone (DEX) to create a synergistic intravitreally injectable dual-drug delivery system. DEX targets chronic inflammation while DNR inhibits excessive cell proliferation as well as suppresses hypoxia-inducible factor 1 to reduce scarring. This pSi-based delivery system releases therapeutic concentrations of DNR for 100 days and DEX for over 165 days after a single dose. This intravitreal dual-drug delivery system is also well tolerated after injection into the rabbit eye model, attested by ocular biomicroscopy, ocular tonometry, electroretinography, and histology. This novel dual-drug delivery system opens an attractive modality for combination therapy to manage refractory chorioretinal diseases and further preclinical studies are warranted to evaluate its efficacy.

Indexed as

AnimalsAntibiotics, AntineoplasticAnti-Inflammatory AgentsDaunorubicinDelayed-Action PreparationsDexamethasoneDrug Delivery SystemsDrug SynergismFemaleMaleMicrospheresParticle SizePorosityRabbitsSiliconSpectroscopy, Fourier Transform InfraredAntibiotics, AntineoplasticAnti-Inflammatory AgentsDaunorubicinDelayed-Action PreparationsDexamethasoneSiliconcontrolled releasedaunorubicindexamethasoneDual-drug loadingintravitreal drug deliveryporous silicon

Identifiers

PMID29996687
PMCPMC6058705
OpenAlexW2869759688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.